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scientometrics of anesthetic drugs and their 
techniques of administration, 1984–2013
Kamen V Vlassakov
igor Kissin
Department of anesthesiology, 
Perioperative and Pain Medicine, 
Brigham and Women’s hospital, 
harvard Medical school, Boston, 
Ma, Usa
Abstract: The aim of this study was to assess progress in the field of anesthetic drugs over 
the past 30 years using scientometric indices: popularity indices (general and specific), rep-
resenting the proportion of articles on a drug relative to all articles in the field of anesthetics 
(general index) or the subfield of a specific class of anesthetics (specific index); index of 
change, representing the degree of growth in publications on a topic from one period to the 
next; index of expectations, representing the ratio of the number of articles on a topic in the 
top 20 journals relative to the number of articles in all (.5,000) biomedical journals covered 
by PubMed; and index of ultimate success, representing a publication outcome when a new 
drug takes the place of a common drug previously used for the same purpose. Publications on 
58 topics were assessed during six 5-year periods from 1984 to 2013. Our analysis showed 
that during 2009–2013, out of seven anesthetics with a high general popularity index ($2.0), 
only two were introduced after 1980, ie, the inhaled anesthetic sevoflurane and the local anes-
thetic ropivacaine; however, only sevoflurane had a high index of expectations (12.1). Among 
anesthetic adjuncts, in 2009–2013, only one agent, sugammadex, had both an extremely high 
index of change (.100) and a high index of expectations (25.0), reflecting the novelty of its 
mechanism of action. The index of ultimate success was positive with three anesthetics, ie, 
lidocaine, isoflurane, and propofol, all of which were introduced much longer than 30 years 
ago. For the past 30 years, there were no new anesthetics that have produced changes in 
scientometric indices indicating real progress.
Keywords: anesthetics, anesthetic adjuvants, mortality, safety margins, therapeutic indices
Introduction
Scientometrics is devoted to the measurement of scientific output (publications) as well 
as of the impact of scientific findings on subsequent developments in related areas of 
research. This study evaluated the evolution of different anesthetics and techniques 
of their administration over the past 4 decades using a number of new scientometric 
indices.1–6 
In the course of this evaluation, our interests were centered on various developments 
related to the use of anesthetic drugs, including the dramatic decrease in anesthesia-
related mortality. Over the past 4 decades, many changes in drugs used for anesthesia 
may have contributed to this decrease. In 1954, Beecher and Todd published a study 
on mortality during the perioperative period, based on 599,548 cases collected from 
ten academic hospitals over 6 years.7 They found that anesthesia was a primary or 
contributory cause of mortality in one per 1,560 cases. Several studies that followed 
(1956–1975) reported comparable rates of mortality.8–11 Presently, the risk related 
to anesthesia is estimated to be approximately ten times lower.12 The strong impact 
of anesthetics on mortality stems from their low margins of safety. As indicated in 
Goodman and Gilman’s Pharmacological Basis of Therapeutics, “the inhalational 
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anesthetics have therapeutic indices (median lethal dose/
median effec  tive dose [LD50/ED50]) that range from 2 to 4, 
making these among the most dangerous drugs in clinical 
use”.13 For example, the experimentally determined (in 
rats) therapeutic index (LD50/ED50) of halothane for motor 
responses is 4.1.14 Over the past 4 decades, many changes 
in drugs used for anesthesia may have contributed to the 
dramatic decrease in mortality and morbidity.
Scientometric assessments of various classes of drugs 
have been reported in a number of publications.1–6 Some 
of the scientometric indices can be used to indicate certain 
changes in drug administration.3,5,6 The main aim of this study 
was to find signs of progress in the use of anesthetics over 
the period 1984–2013.
Methods
The following scientometric parameters4–6 were used as signs 
of progress in assessment of anesthetics.
general popularity index
The general popularity index (GPI) is the percentage of 
articles on a specific anesthetic among all articles on anes-
thetics (Anesthetics [MeSH term]) published over the same 
5-year period. A specific threshold of 0.1% for 2009–2013 
(arbitrary) was used to select topics for which the number 
of publications reached a notable level.
Specific popularity index
The specific popularity index (SPI) is the number of articles 
on a specific anesthetic used to provide one of the following 
types of anesthesia: inhalational anesthesia (Anesthesia, Inha-
lation [MeSH term]), intravenous anesthesia (Anesthesia, 
Intravenous [MeSH term]), or local anesthesia (Anesthesia, 
Local [MeSH term]), presented as a percentage of all articles 
on the appropriate type of anesthesia (for example, “Lido-
caine AND Anesthesia, Local” as a percentage of all articles 
with term “Anesthesia, Local”). Publications were counted 
for each 5-year period starting with 1979–1983.
index of change
The index of change (IC) is the percentage change in the num-
ber of publications on a drug or technique during a 5-year (or 
10-year) period compared with the previous similar period. It 
reflects the change in general interest in a topic. The specific 
threshold used for this index was $50, ie, the growth beyond 
the increase (percent) in number of publications in the whole 
field of PubMed drug-related articles (Drug [MeSH term]) 
during the same time interval.
index of expectations
The index of expectations (IE),or Top Journal Selectivity 
Index, is the ratio of the number of all types of articles on a 
particular topic in the top 20 journals relative to the number 
of articles in all (.5,000) biomedical journals covered by 
PubMed over 5 years, reflecting the level of interest in the 
top journals. An index value $10 was selected to represent a 
high expectation of success. The 20 top journals were selected 
based on two factors, ie, their rank sorted by impact factor, 
as indicated by Journal Citation Report for 2013, and the 
journal specialty area. They included pharmacology, anes-
thesia, pain, and surgery (ten journals), and general biomedi-
cal journals (also ten journals), as follows: Anesthesiology, 
Annals of Internal Medicine, Annals of Surgery, British 
Journal of Anaesthesia, British Journal of Surgery, British 
Medical Journal, Journal of American College of Surgeons, 
Journal of American Medical Association, Journal of Clini-
cal Investigation, Journal of Clinical Pharmacology and 
Therapeutics, Journal of Pharmacology and Experimental 
Therapeutics, The Lancet, Nature, Nature Medicine, Nature 
Reviews Drug Discovery, New England Journal of Medicine, 
Pain, Proceedings of the National Academy of Science of the 
United States of America, Science, Trends in Pharmacologi-
cal Sciences.
index of ultimate success
Index of ultimate success (IUS) is a publication outcome 
indicating that a new drug (or group of drugs) has taken the 
place of a drug that had previously been commonly used for 
the same purpose. It is measured by the degree of decline in 
SPI of an old, supplanted drug. Decline in the SPI of a sup-
planted drug $50% during an interval of 10–20 years was 
selected to represent a positive IUS for the new drug.
The articles were counted using the National Library of 
Medicine’s PubMed website (http://www.ncbi.nlm.nih.gov/
pubmed/) which covers over 21 million journal articles in 
biomedicine. Various individual anesthetic drug names or 
terms related to the techniques of their administration were 
entered in the search box. Filter for languages (English) was 
used. All types of articles were considered.
The criterion for selection of a particular drug for analysis 
was the level of its GPI in 2009–2013. If the GPI was $0.1, 
the drug was also assessed using SPI. The IC and IE were 
determined if the following two criteria were satisfied: the 
last of the initial 100 articles on a topic was published after 
1980 and the number of articles in 2009–2013 was $50. IUS 
was calculated when a new drug caused a stable decline over 
10–15 years in SPI of an alternative drug.Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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The following categories of terms were included in 
the searches: anesthetics (inhaled, intravenous, and local); 
anesthetic adjuncts (all drugs that are used to modify the 
main effects of anesthetics, including analgesics, sedatives, 
neuromuscular blocking agents with antagonists, and alpha 
2-selective adrenergic receptor agonists); and techniques 
used for anesthetic administration (methods of measuring 
the main anesthetic effect, ie, depth of sedation, are also 
included in this category).
The terms were selected from various sources.15–20 The 
following terms were searched: “alfentanil”, “atracurium”, 
“benzocaine”, “bispectral index”, “bupivacaine”, “buprenor-
phine”, “chloroprocaine”, “cisatracurium”, “clonidine”, 
“closed-loop anesthesia”, “combined spinal-epidural”, 
“continuous epidural”, “continuous nerve block”, “continu-
ous spinal”, “desflurane”, “dexamethasone”, “dexmedetomi-
dine”, “diazepam”, “edrophonium”, “enflurane”, “entropy”, 
“etomidate”, “fentanyl”, “gantacurium”, “halothane”, 
“isoflurane”, “ketamine”, “levobupivacaine”, “lidocaine”, 
“median electroencephalographic frequency”, “mepi-
vacaine”, “methohexital”, “midazolam”, “mivacurium”, 
“morphine”, “neostigmine”, “nitrous oxide”, “pancuronium”, 
“  prilocaine”, “procaine”, “propofol”, “pyridostigmine”, 
“remifentanil”, “robotic anesthesia”, “rocuronium”, “ropi-
vacaine”, “sevoflurane”, “spectral edge frequency”, “succi-
nylcholine”, “sufentanil”, “sugammadex”, “target-controlled 
anesthesia”, “tetracaine”, “thiopental”, “total intravenous 
anesthesia”, “ultrasound-guided block”, “vecuronium”, 
“volatile induction”, “wound infiltration”, and “xenon”.
Results
anesthetics
Table 1 indicates that, in 2009–2013, 19 anesthetics had a 
GPI $0.1, comprising six inhaled, four intravenous, and nine 
local anesthetics. Of the four that were introduced after 1980, 
two are inhaled anesthetics (sevoflurane and desflurane) and 
the other two are local anesthetics (ropivacaine and levobupi-
vacaine). Of the 19 anesthetics with a GPI $0.1, seven were 
higher than 2.0, comprising isoflurane, nitrous oxide, and 
sevoflurane (among inhaled anesthetics), propofol (among 
intravenous anesthetics), and lidocaine, bupivacaine, and 
ropivacaine (among local anesthetics).
Table 1 Popularity indices (gPi and sPi) of anesthetics
Name Introductiona Number of articles  
(2009–2013)
GPI (%)b  
(2009–2013)
SPI (%)c
1989–1993 1994–1998 1999–2003 2004–2008 2009–2013
Inhaled anesthetics
Isoflurane 1971 2,048 4.5 28.7 35.2 31.3 30.6 28.4
nitrous oxide 1844 1,836 4.0 26.2 23.5 20.9 15.3 11.8
Sevoflurane 1987 1,666 3.7 3.2 14.8 27.0 30.8 32.6
halothane 1956 406 0.9 28.8 23.6 15.9 8.8 3.6
Desflurane 1990 402 0.9 3.6 9.2 6.7 9.3 7.8
Enflurane 1968 53 0.1 10.3 6.4 2.4 1.2 0.5
Intravenous anesthetics
Propofol 1977 3,957 8.7 19.0 24.5 34.7 36.9 34.9
Thiopental 1934 399 0.9 9.6 8.9 5.7 4.2 2.5
etomidate 1973 386 0.8 2.2 2.1 2.0 2.3 2.0
Methohexital 1960 37 0.1 2.2 1.8 1.4 0.6 0.4
Local anesthetics
lidocaine 1947 3,667 8.1 22.8 25.3 22.4 19.8 17.5
Bupivacaine 1963 2,230 4.9 11.3 18.1 18.2 16.6 14.4
ropivacaine 1996d 936 2.1 1.2 1.4 7.1 6.9 5.9
levobupivacaine 1995 379 0.8 – – 1.3 3.3 3.4
Procaine 1905 326 0.7 3.2 1.5 1.2 1.1 0.8
Prilocaine 1960 302 0.7 3.8 4.0 3.3 2.2 2.2
Tetracaine 1932 245 0.5 2.5 3.0 2.1 1.4 1.1
Mepivacaine 1957 211 0.5 2.2 2.4 2.4 2.0 1.4
Benzocaine 1902 170 0.4 0.4 0.6 0.9 0.5 0.5
Notes: Only anesthetics with 2009–2013 gPi $0.1 are included. Xenon and chloroprocaine did not reach this threshold. aas indicated in Miller’s Anesthesia or Cousin’s 
and Bridenbaugh’s Neural Blockade.  bgPi share of all articles on anesthetics (anesthetics [Mesh term]) published in 2009–2013.  csPi share of all articles on one of the 
following types of anesthesia: inhalational anesthesia (anesthesia, inhalation [Mesh term]), intravenous anesthesia (anesthesia, intravenous [Mesh term]), or local anesthesia 
(anesthesia, local [Mesh term]). dYear of approval by US Food and Drug Administration. Bold font underlines that in contrast to the values in five other columns, values in 
this column represent different type of calculations: shear of articles on anesthetics, not share of articles on appropriate type of anesthesia.
Abbreviations: GPI, general popularity index; SPI, specific popularity index.Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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The SPI indices are presented in Table 1 (right side) and 
in Figures 1–3. They indicate that changes in the   popularity of 
anesthetics are usually very slow, with some having high SPIs 
for a very long time. For example, for the past 40–50 years, 
the SPI of lidocaine was amazingly stable at 22 in both 
1964–1968 and 1999–2003, then there was a slight decline 
to 18 (2009–2013). Nitrous oxide was also highly popular 
for a long time; however, its popularity has decreased over 
the past 10 years.
As indicated by Table 2, only five anesthetics met our 
criteria to measure IE and IC, ie, three general anesthet-
ics (propofol, sevoflurane, and desflurane) and two local 
anesthetics (ropivacaine and levobupivacaine). In 2009–
2013, only sevoflurane and desflurane had an IE higher 
than the specific threshold of 10, indicating the persistence 
of high expectations for these agents. At the same time, 
in 2009–2013, the IC of all five of these drugs was rather 
low, probably indicating that interest in them has peaked. 
Table 3 presents the IUS for various anesthetic drugs; lido-
caine, isoflurane (combined with sevoflurane), and propofol 
all reached 50% 10–20 years after their introduction.
anesthetic adjuncts
Anesthetic adjuncts are presented in Table 4. In 2009–2013, 
only three drugs demonstrated both impressive increases in 
interest (IC .50) and high expectations (IE .10), ie, rocuro-
nium, sugammadex (an agent for reversal of rocuronium-
induced neuromuscular block), and dexamethasone (when 
used as an adjunct to local anesthetics). However, only 
sugammadex had a very high IE (25.0).
Techniques
Table 5 shows that among the techniques used for anes-
thetic administration during 2009–2013, there was a high   
IE (.10) for target-controlled anesthesia (14.6), bispectral 
index (14.6), and entropy (20.8), the latter two being pro-
cessed electroencephalogram techniques for monitoring 
depth of anesthesia. However, in 2009–2013, the IC for 
these terms did not reach the specific threshold level of 50. 
Ultrasound-guided block had very high levels of IC over 
all recent 5-year periods, indicating a dramatic increase in 
the use of the technique. At the same time, the IE for this 
technique was above the specific threshold level of 10 in 
1999–2003 and in 2004–2008; however, in the most recent 
period (2009–2013), its IE had already declined to 6.9. Dur-
ing 2004–2008, continuous nerve block had high values for 
both IC and IE, but in 2009–2013 they fell below the specific 
threshold levels.
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rate of publication growth
The rates of 5-year publication growth for each of three 
classes of anesthetics (inhaled, intravenous, and local) are 
presented in Figure 4. In general, the most significant growth 
was with local anesthetics and the least significant was with 
inhaled anesthetics. In addition, the most obvious periods 
of growth for all classes of anesthetics were 1984–1988 
and 1989–1993; however, for the past 20 years, growth was 
almost absent. This phenomenon is especially evident in 
Figure 5, which compares 10-year growth of publications 
on anesthetic-related articles with that of all PubMed drug-
related articles (entire pharmacology) and that of all articles 
related to anesthesia monitoring. In 2004–2013, only growth 
in articles on anesthesia monitoring was comparable with 
that of publications on all drugs in general.
Discussion
This is the first study that used specific scientometric indices 
to determine the evolution in use of anesthetics and to assess 
signs of progress in the field of anesthesia. It demonstrated 
that scientometric indices, suggested before1–6 and used in 
this study, can determine evolution of drugs through their 
presence in articles published in the academic journals. The 
results presented here indicate that over the past 30 years 
there were no new anesthetics that produced changes in 
scientometric indices indicating real progress. The dramatic 
decrease in anesthesia-related mortality is probably due not 
so much to the increased safety margins of new anesthet-
ics, but to the improvements in safety rules related to their 
administration (eg, new anesthesia monitoring techniques 
and better anesthesiologists training).
anesthetics
Our findings indicate that in 2009–2013 no anesthetics 
showed impressive increases in both IC and IE. Two recently 
introduced drugs, the local anesthetics ropivacaine and 
levobupivacaine, which previously demonstrated strong 
increases in IC and IE, had indices below specific threshold 
levels. For example, in 2009–2013, the IE levels for both 
drugs (8.4 for ropivacaine and 6.9 for levobupivacaine) did 
not indicate high expectations. In addition, their SPI (either 
in 1999–2003 or 2004–2008) did not begin high and did not 
increase in 2009–2013 (Table 1). Both drugs were developed 
based on experimental findings that systemic toxicity (mostly 
cardiotoxicity) of racemic bupivacaine was more pronounced 
with the R-enantiomer. As a result, the S-enantiomer prepara-
tions of ropivacaine and levobupivacaine were introduced 
to provide long-acting agents with greater safety margins. 
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Despite the lack of good clinical evidence, but with the reli-
able results of experimental studies, the conclusion was made 
that ropivacaine is less cardiotoxic than other long-acting 
local anesthetics.21,22 Conclusions on the systemic toxicity 
of levobupivacaine seem to be less certain.
As far as general anesthetics are concerned, there were no 
dramatic increases in either IC or IE in 2009–2013; instead, 
only a steady decline of the very high indices following 
their introduction. The best example is desflurane, which 
was introduced in 1990. Its IC was very high in 1994–1998 
but then plummeted to almost zero for the next 15 years 
(Table 2). The SPI of desflurane (Table 1) began to increase 
in 1994–1998, but remained static over the following 15-year 
period. This reflected a steep rise in the popularity of sevoflu-
rane. The SPI of general anesthetics revealed the outcomes 
for another index that requires a long time to develop, ie, 
the IUS. As stated above, the most important outcome of 
the introduction of a new drug is the decline in the number 
of articles about another drug that previously dominated 
use for the same purpose.6 Figure 1 and Table 3 illustrate 
that isoflurane (in combination with sevoflurane) displaced 
halothane in medicobiological journals over the period of 
30 years. Among the intravenous anesthetics, propofol had 
similar success (Figure 2 and Table 3), almost completely 
displacing thiopental. Among local anesthetics, lidocaine 
successfully supplanted procaine (Figure 3 and Table 3). As 
a result, it was not until 10–20 years after their introduction 
that the IUS of these anesthetics reached the level of 50. 
After all, these agents were introduced long ago (lidocaine 
in 1947, isoflurane in 1971, and propofol in 1977). 
anesthetic adjuncts
Among the anesthetic adjuncts, only three drugs demon-
strated increases above the specific threshold levels for both 
IC and IE, ie, rocuronium and sugammadex among general 
anesthetics, and dexamethasone with local anesthetics 
(Table 3). Rocuronium is a nondepolarizing neuromuscular 
blocking agent used to relax skeletal muscles without increas-
ing the depth of anesthesia. Although it was introduced fairly 
long ago (in 1994), the increased interest in this drug seen in 
2009–2013 is probably associated with successful develop-
ment of sugammadex, an agent for the reversal of neuromus-
cular blockade induced by rocuronium (or other steroidal 
nondepolarizing agents) via a novel mechanism of action.23 
The IC and IE for sugammadex (.100 and 25, respectively) 
indicate considerable interest and high expectations.
In 2009–2013, dexamethasone, used as an adjunct to 
local anesthetics, had values above the specific threshold Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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attenuating the release of inflammatory mediators, several 
other properties of dexamethasone may also be important 
for this effect.24
Techniques
In 2009–2013, not a single technique demonstrated increases 
of both IC and IE above the specific threshold levels. The best 
results, although below these threshold levels in combination, 
were for target-control anesthesia (IC 29 and IE 14.6) and 
for continuous nerve block (IC 42 and IE 9.5). It should be 
noted that the increases in IC for ultrasound-guided block 
were above the specific threshold level for all 5-year periods, 
starting with 1999–2003, indicating extremely high interest 
in the technique; however, IE was only 6.9 in 2009–2013. 
This technique completely supplanted (within a little more 
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levels for both IC and IE (.100 and 10.1, respectively). 
These values are not significantly lower for dexmedeto-
midine (.100 and 9.0, respectively), which is primarily 
used as a sedative and intravenous coanesthetic. Coadmin-
istration of local anesthetics and α2 adrenergic agonists 
(clonidine or dexmedetomidine) or the corticosteroid 
dexamethasone provide ways to prolong peripheral nerve 
blockade without increasing the dose of local anesthetics 
and to avoid approaching the limits of the narrow thera-
peutic windows of local anesthetics. However, perineural 
administration has not yet been approved by the US Food 
and Drug Administration for either agent. Dexamethasone 
can be used (to prolong local anesthetic blockade and 
analgesia) perineurally or via systemic administration. 
Although its beneficial effect is thought to be mediated by Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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than a decade) the previously used techniques of paresthesia 
and nerve stimulation for needle guidance.
The opposite combination of changes in both indices was 
observed with entropy (a processed electroencephalogram 
for monitoring depth of anesthesia): in 2009–2013, IE was 
high (20.8) and IC was low (4). A similar phenomenon was 
observed with another processed electroencephalogram, ie, 
bispectral index: although the IE was high for all 5-year 
periods since its introduction, including in 2009–2013 (14.6), 
the IC was very low (-3 in 2009–2013). The above results 
show high expectations related to techniques that measure 
and monitor the effect of general anesthetics. At the same 
time, one cannot exclude the role of extensive marketing for 
these techniques.
rate of publication growth
The lack of success with new anesthetics coincides with 
declining rates of publication growth for all three types of 
agents, ie, inhaled, intravenous, and local. With inhaled 
anesthetics, growth was low during all three 10-year peri-
ods, 1984–1993, 1994–2003, and 2004–2013 (Figure 5). 
With intravenous and local anesthetics, the rate of growth 
in 1984–1993 was at the level of growth with all PubMed 
drug-related articles (close to 60%); however, in the next two 
10-year periods it progressively declined to almost zero in 
2004–2013. These declines were not a sign of the absence of 
research growth in anesthesia in general. The best example 
of growth is the research efforts in the field of anesthesia 
monitoring, which profoundly exceeded those in other 
drug-related fields during 1984–1993. During the two other 
10-year periods (1994–2003 and 2004–2013), the growth in 
monitoring was on the level with growth among all PubMed 
drug-related articles.
Margins of safety
Margins of safety are very low with all classes of anesthetics, 
and major efforts to improve the safety margins of these agents 
have yielded sparse results. As indicated in the introduction, 
inhaled anesthetics have very low therapeutic indices, making 
them “among the most dangerous drugs in clinical use”.13 This 
was the main reason for the high mortality and morbidity of 
general anesthesia. Substituting isoflurane and sevoflurane 
for halothane (Figure 1) likely improved the safety of anes-
thesia; for example, concerns regarding hepatic injury with 
inhalational anesthesia seem to have disappeared. Notably, 
the experimentally determined therapeutic index of isoflurane 
is better than that of halothane. In rats the LD50/ED50 index 
for motor responses with isoflurane is 1.7 times higher than 
with halothane.14 However, the margins of safety of inhaled 
anesthetics are still too low.
Therapeutic indices (LD50/ED50) for intravenous anes-
thetics in general are not much better than those for inhaled 
anesthetics. However, the therapeutic index of intravenous 
anesthetics varies much more than that of inhaled anesthetics. 
For example, the LD50/ED50 index for motor responses in rats 
is 3.1 times higher with etomidate than with thiopental.25 
The greater margin of safety in combination with good 
hemodynamic stability led to the initial widespread use of 
etomidate, especially in critically ill patients. However, one 
specific side effect, adrenocortical suppression, has tempered 
the enthusiasm of anesthesiologists for etomidate. Efforts are 
currently directed toward creation of an etomidate analog that 
offers the beneficial properties of this drug without significant 
adrenocortical suppression.26
Local anesthetics, if used in large doses to produce epidu-
ral anesthesia or blockade of peripheral nerves, also pose the 
problem of low margins of safety, but to a lesser degree than 
general anesthetics. Similarly, reported mortality seems to be 
lower with regional anesthesia than with general anesthesia, 
according to some studies by about a third.27,28
Insufficient progress in finding new anesthetics with 
appreciably better margins of safety has led anesthesiologists 
to redouble their efforts to compensate for this drawback. 
This work has developed along two basic directions, ie, 
better training of anesthesia providers and improvements in 
the technology of anesthesia monitoring. The first direction 
produced the present situation: a physician with 3 years of 
anesthesia residency training, or a closely supervised nurse 
anesthetist, usually gives minute-by-minute undivided atten-
tion to the status of each anesthetized patient. The other direc-
tion has produced various techniques for patient monitoring, 
such as oximetry, capnography, quantitative neuromuscular 
blockade monitoring, and processed electroencephalography 
monitoring, many of which have become standard world-
wide. As a result of improved vigilance (“vigilance” has been 
the motto of the American Society of Anesthesiologists), 
anesthesiology reached an exceptional position among the 
branches of medicine and became a model for patient safety.29 
Therefore it is possible that the decrease in anesthesia-related 
mortality over the past 30–40 years (approximately 10-fold 
lower compared with 1954–1975) was not produced by the 
development of anesthetics with better margins of safety, but 
mostly by improved vigilance while using anesthetics with 
low margins of safety.
The scientometric indices used to identify signs of 
progress in the therapeutics (GPI, SPI, IC, IE, and IUS) are Drug Design, Development and Therapy
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based on the link between the number of publications and 
the progress in pharmacotherapy. However, this link is inher-
ently weak. This weakness is underlined by the fact that the 
mere number of publications does not differentiate between 
publications characterizing a drug in a positive or negative 
way. Therefore, scientometric indices should be assessed 
in combination with results on drug effectiveness based on 
good quality evidence. The indices used here have different 
degrees of reliability in demonstrating a drug’s progress: 
from the lower levels with GPI, SPI, IC, and IE to a higher 
level with IUS.
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